Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes

Maiorino, Maria Ida; Volpe, Elisabetta; Olita, Laura; Bellastella, Giuseppe; Giugliano, Dario; Esposito, Katherine

doi:10.1007/s12020-014-0277-z

Cited by 15 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KDR?CD133? cell count are reduced in young type 1 diabetic patients compared with controls, particularly in those with suboptimal glucose control [5,12], longer diabetes duration and microangiopathy [19], and signs/surrogates of macroangiopathy [14,20]. Moreover, in agreement with previous findings [5], we demonstrated an inverse correlation between glucose variability, as measured as MAGE, and CD34?KDR?CD133?…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study

et al. 2015

Self Cite

View full text Add to dashboard Cite

Circulating endothelial progenitor cells (EPCs) are involved in the repairing mechanisms of vascular damage. Glucose variability may contribute to the development of chronic vascular complications of diabetes. We evaluated whether reducing glucose variability with continuous subcutaneous insulin infusion (CSII) would increase circulating levels of EPCs in type 1 diabetes. The study population consisted of 106 type 1 diabetic patients: 41 subjects considered eligible for CSII completed a 6-month follow-up. Sixty-five patients on intensified insulin therapy with multiple daily injections served as control group. Seven EPCs phenotypes were assessed by flow cytometry, and glucose variability by mean amplitude of glycemic excursions (MAGE). Both CD34+KDR+ [difference between groups 32.0, 95 % CI (19.6-44.4) number/10(6) cells, P < 0.001] and CD34+KDR+CD133+ [12.5 (5.5-19.5), P < 0.001)] cell count increased at endpoint in the CSII group, associated with a reduction of MAGE [-1.1 (-2.1 to -0.1), P = 0.026]. No changes occurred in the control group. In multivariate analyses, changes in MAGE were independently associated with changes in both CD34+KDR+ (P = 0.019) and CD34+KDR+CD133+ (P = 0.022) cell count. Reducing glucose variability with CSII in type 1 diabetes increases circulating EPCs levels, suggesting a novel mechanism of vascular damage by oscillating glucose.

show abstract

Section: Discussionsupporting

confidence: 91%

“…In a cross-sectional study of 40 subjects with type 1 diabetes, we found an inverse correlation between glucose variability, and circulating EPCs levels [12]. We hypothesized that reducing glucose variability would ameliorate EPCs outlook in type 1 diabetes.…”

Section: Introductionmentioning

confidence: 89%

Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Endothelial progenitor cells (EPCs) are bone marrow derived circulating cells with the ability to differentiate into mature endothelium and participate in neoangiogenesis [3]. EPCs are characterized by the expression of stem cell markers, such as cluster of differentiation (CD) 34 and CD133, and endothelial markers, such as kinase domain region (KDR) [4]. CD34 + CD133 + KDR + cells have been used as surrogate of human circulating EPCs.…”

Section: Introductionmentioning

confidence: 99%

Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients

Chen

Leng

et al. 2017

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

Endothelial dysfunction is associated with the risk of cardiovascular complications in diabetic patients. Endothelial progenitor cells (EPCs) and flow-mediated dilation (FMD) are common markers of endothelial function. In this study, we aim to investigate whether the DPP-4 inhibitor saxagliptin modulate EPCs number and FMD in newly diagnosed, treatment-naive type 2 diabetic patients. This was a controlled, randomized, open-label clinical trial. Saxagliptin group and metformin group consumed either saxagliptin 5 mg per day or metformin 1 500 mg per day respectively for 12 weeks. Changes of FMD and EPCs number after 12-week intervention were the primary endpoints. 31 patients were initially enrolled and randomized to saxagliptin group (n=16) and metformin group (n=15). 27 patients completed the trial (saxagliptin group n=14 and metformin group n=13), and 4 patients dropped out during the study. FMD and EPCs number increased significantly in both saxagliptin group and metformin group, and there was no significant difference between groups. 2-h postprandial plasma glucose, HbA1c and diastolic blood pressure improved significantly in both groups, and there was no significant difference between groups. Saxagliptin and metformin had comparable beneficial effects on endothelial function.

show abstract

“…Lending support to this view is the fact that patients with well-controlled diabetes and low HbA1c levels nevertheless develop chronic and acute complications. Maiorino et al [29] and Škrha et al [30] have assumed that there are pathophysiological premises suggesting that glycaemic variability may cause damage to the wall of blood vessels, especially to the endothelium.…”

Section: Discussionmentioning

confidence: 99%

Acute Responses to Low and High Intensity Exercise in Type 1 Diabetic Adolescents in Relation to Their Level of Serum 25(OH)D

et al. 2020

View full text Add to dashboard Cite

The main purpose of this study was to investigate the differences in glycaemic reaction in response to various physical activities in 20 young boys (14.4 ± 1.6 years) with type 1 diabetes mellitus (T1DM) and with either vitamin D deficiency or with suboptimal levels of vitamin D. Participants were divided into two groups (deficiency group-DG, n = 10; suboptimal group-SG, n = 10) according to their vitamin D levels. All patients performed aerobic and mixed (aerobic-anaerobic) physical efforts. During the exercise, the respiratory responses and glucose levels were monitored. Biochemical blood analyses were performed before each physical effort. The oxygen consumption was not significantly lower in SG during both aerobic and mixed effort (4.0% and 5.6%, respectively). The glycated haemoglobin (HbA1c) level was higher by 6.1% and the total daily dose of insulin (DDI) was higher by 18.4% in the DG. The differences were not statistically significant. Patients with lower vitamin D levels demonstrated an insignificantly higher glycaemic variability during days with both aerobic and mixed exercises. An appropriate vitamin D concentration in T1DM patients' blood may constitute a prophylactic factor for hyperglycaemia during anaerobic training and hypoglycaemia during aerobic training.

show abstract

Glucose variability inversely associates with endothelial progenitor cells in type 1 diabetes

Cited by 15 publications

References 15 publications

Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study

Reducing glucose variability with continuous subcutaneous insulin infusion increases endothelial progenitor cells in type 1 diabetes: an observational study

Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients

Acute Responses to Low and High Intensity Exercise in Type 1 Diabetic Adolescents in Relation to Their Level of Serum 25(OH)D

Contact Info

Product

Resources

About